China National Medical Insurance Administration announced the first Chinese crown -produced oral medicine, Azf fixed film has passed preliminary review, saying that it will strive to be reasonable in reasonableThe price is officially included in the medical insurance directory.notThe Beijing Daily reported on Wednesday (September 7) that the National Medical Insurance Administration recently reviewed the drug declaration materials adjusted by the medical insurance drug catalog in 2022.The first Chinese crown -producing crown -taking medicine Azf fixed table has been adjusted by the national medical insurance catalog.notAccording to the National Medical Insurance Bureau, preliminary form reviews can ensure that the application of the application of the application meets the application conditions, on the other hand, review the integrity and standardization of the declaration data, and verify the authenticity of some data to the relevant parties of the data according to the work needs.notIn the context of the normalization of the crown disease epidemic prevention and control, from the first implementation of the independent application system of the medical insurance drug directory enterprise in 2020, the State Medical Insurance Administration attaches great importance to the treatment of coronary virus treatment drugs.notAccording to the Medical Insurance Bureau, during the application process, the treatment drugs that have passed the coronary virus that have passed the formal review will carry out follow -up work in accordance with the procedure and strive to officially include the medical insurance directory at a reasonable price.notIn the second review, a total of 344 kinds of drugs were reviewed by preliminary forms, including 199 types of over -catalogs such as Azf's fixed tablet, including 145 types of western medicines and Chinese medicines such as Chinese medicine and Ada Mibu.%, Compared with 2021, the number of drugs that are reviewed and reviewed by preliminary forms has increased to a certain extent.
